NCT07816341尚未招募1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of F182112 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
Institute of Hematology & Blood Diseases Hospital, China1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2026年10月10日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This is an open-label, phase I clinical study of F182112 in patients with relapsed or refractory autoimmune hemolytic anemia (AIHA). Participants will receive F182112 at different dose levels. The main purpose of the study is to evaluate the safety and tolerability of F182112 and to identify an appropriate dose for further clinical development.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years.
- •Diagnosis of AIHA according to established Chinese or international criteria, including warm AIHA, mixed AIHA, cold agglutinin disease, or Evans syndrome.
- •Refractory to multiple lines of therapy, meeting all of the following: HGB <100 g/L with evidence of hemolytic anemia; Prior treatment with ≥2 immunosuppressive therapies, including a CD20 monoclonal antibody; Glucocorticoid treatment for ≥3 months, unless contraindicated or intolerable; Adequate prior CD20 monoclonal antibody treatment (≥4 doses of 100 mg or 375 mg/m², or 2 doses of 1,000 mg).
- •ECOG performance status ≤
- •Participants and their partners agree to use effective contraception from informed consent through 1 year after study treatment.
- •Written informed consent must be obtained before any study-specific screening procedures.
排除标准
- •Diagnosed lymphoproliferative malignancy.
- •Secondary AIHA caused by drugs or infection.
- •Congenital immunodeficiency or other inherited or acquired hemolytic disorders.
- •Prior organ or hematopoietic stem cell transplantation.
- •New thrombotic events or organ infarction within 6 months before enrollment.
- •Prior BCMA-targeted therapy within 6 months before enrollment.
- •Any of the following prior treatments within the specified washout periods: Anti-CD20 monoclonal antibody within 12 weeks; Sutimlimab or other approved biologic therapy within 5 half-lives; Plasma exchange within 4 weeks; Splenectomy within 12 weeks.
- •Any of the following cardiovascular conditions: LVEF ≤45%; Active cardiac disease or NYHA class III/IV heart failure; Clinically significant arrhythmia requiring treatment, except atrial fibrillation or paroxysmal supraventricular tachycardia; QTc ≥450 ms in males or ≥470 ms in females; Myocardial infarction, coronary artery bypass grafting, or coronary stent placement within 6 months; Other clinically significant cardiac disease considered unsuitable by the investigator.
- •Unstable systemic disease, including severe hepatic or renal disease requiring treatment.
- •History of another primary malignancy within 5 years before screening, except adequately treated non-melanoma skin cancer, carcinoma in situ, or other malignancies without recurrence for ≥5 years.
- •Major surgery within 4 weeks before screening if considered unsuitable for enrollment by the investigator.
- •Uncontrolled active fungal, viral, bacterial, tuberculosis, or other infection, or infection requiring intravenous antimicrobial therapy.
- •Active or clinically significant HBV, HCV, HIV, or syphilis infection
- •Live-virus vaccination within 4 weeks before enrollment.
- •Participation in another interventional clinical study within 5 half-lives of the investigational treatment before screening, or planned use of another investigational treatment during this study.
- •Pregnant or breastfeeding women.
- •Psychiatric disorders, impaired consciousness, or central nervous system disorders, including a history of epilepsy or Parkinson's disease.
- •Known hypersensitivity to any component of F
- •Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
研究组 & 干预措施
F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia
Experimental
F182112 is a recombinant humanized anti-BCMA/CD3 bispecific antibody for injection. By binding to CD3 receptors on T cells, F182112 can effectively deplete BCMA-expressing B cells and plasma cells in vivo, thereby alleviating the clinical manifestations of autoimmune diseases.
干预措施: F182112 single-agent (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: 28 days post the last dose treatment
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 6 to assess the adverse event
次要结局
未报告次要终点
研究者
Jun Shi
Director of the Red Blood Cell Diseases Center and Regenerative Medicine Center
Institute of Hematology & Blood Diseases Hospital, China
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell LymphomaRelapsed/Refractory B-cell LymphomaDiffuse Large B-cell LymphomaInert B-cell Lymphoma Transformed Into Large B-cell Lymphoma (Excluding Richter Transformation, THRLBCL, and BL)NCT07539688Institute of Hematology & Blood Diseases Hospital, China18
尚未招募
1 期
A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT07760454UCARsgen Biotech Limited68
尚未招募
1 期
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.Small Cell Lung CancerNCT07559929Hangzhou DAC Biotechnology Co., Ltd.200
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back PainNCT07641504Eli Lilly and Company150
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis PainOsteoarthritis, KneeNCT07641517Eli Lilly and Company150